Announces termination of monthly KPI flash report disclosures and states that going forward information will be disclosed via quarterly financial presentation materials and financial summaries. The reports cover through October 2026 monthly data; no disclosures from November 2026 onward. An overview of the current status and results of regenerative medicine-related businesses is provided.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4880","jir_company_name":"CellSource Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4880-20261111-02.pdf","jir_short_summary":"Announces termination of monthly KPI flash report disclosures and states that going forward information will be disclosed via quarterly financial presentation materials and financial summaries. The reports cover through October 2026 monthly data; no disclosures from November 2026 onward. An overview of the current status and results of regenerative medicine-related businesses is provided.","jir_summary":"### Change in IR Policy and Background\nCellSource has decided to terminate the disclosure of monthly KPI flash reports for the contracted processing services business. To enhance transparency and reliability for investors, the company determined that quarterly-based disclosures are more appropriate for monitoring the progress of its business strategy. The monthly KPI flash report will end with the October 2026 monthly report, and no reports will be disclosed thereafter. Going forward, the company will provide information useful for investment decisions through quarterly financial presentation materials and financial summaries.\n\n### Company Overview and Business Areas\nCellSource promotes the industrialization of regenerative medicine and offers regenerative medicine-related services including contracted processing of adipose-derived stem cells, synovium-derived stem cells, and blood, provision of regenerative medicine services, and regulatory compliance support. The company is a permitted manufacturing facility for specified cell-processed products (FA3240004) and receives numerous processing contracts while advancing services for medical institutions and research and development.","jir_financial_highlights":"Disclosure of monthly KPI flash reports: Terminated (Unknown)\nPublic information disclosure policy: Transition to disclosure via quarterly financial presentation materials and financial summaries (Unknown)","jir_category":"","jir_hashtags":"#CellSourceCoLtdIR, #MonthlyKPIFlashReportEnded","jir_key_figures":"Termination of monthly KPI flash report disclosure\nTransition to information disclosure via quarterly financial presentation materials and financial summaries\nMonthly KPI flash reports end with the October 2026 monthly report; no disclosures from November 2026 onward","jir_meta_title":"CellSource Co., Ltd. Notice: Termination of Monthly KPI Flash Report Disclosure | November 2026","jir_meta_description":"CellSource announces the termination of monthly KPI flash report disclosures for its contracted processing services business. Going forward, information will be disclosed via quarterly financial presentation materials and financial summaries. Overview of regenerative medicine-related business status and the new disclosure policy.","jir_og_title":"CellSource IR: Notice of Termination of Monthly KPI Flash Reports","jir_og_description":"CellSource announces the end of monthly KPI flash report disclosures and explains the new information disclosure policy and an overview of its regenerative medicine-related business.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59237,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-149192","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n